GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
The Silent Challenge of Early Alzheimer’s Detection
Discover how researchers use AI and machine learning algorithms on routine electronic health records to spot early Alzheimer’s risk up to 7 years before symptoms appear.
Canine Biomarkers & Trial Overhauls: This Week’s Top Alzheimer’s Discoveries
Explore October 2026 breakthroughs in Alzheimer's research, including Colorado State's canine dementia models, Cleveland Clinic's trial overhaul framework, and new p-tau217 plasma insights.
The Regulatory Shift: From Optional Inclusion to Mandatory Action
Learn how Glassbury AI bridges grassroots engagement and LLM companions to meet FDA Diversity Action Plan compliance and solve Alzheimer's trial enrollment.
The Regulatory Shift: Why Diversity Is Now a Technical Requirement
Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.
AI Meets the Genome: The September 2026 Breakthroughs Decoding Alzheimer’s
Discover how AI models analyzing structural 3D genome folding and speech biometrics published in mid-September 2026 are cracking Alzheimer's mysteries.
Beyond Plaques & Tangles: The Brand-New Genomic & Micro-Wiring Discoveries Reshaping Alzheimer’s
Explore brand-new September 2026 breakthroughs in Alzheimer's research, from Salk's hidden microproteins to 3D genome folding and protective brain wiring.
The Dawn of a New Era in Alzheimer’s Care: From Simple Blood Tests to At-Home Treatments
Discover how the new p-tau217 blood test and the LEQEMBI IQLIK® autoinjector are revolutionizing Alzheimer's diagnosis and treatment at home.
Alzheimer’s Breakthroughs: Atypical Variants and New Pathways
Discover how modern neurology is moving beyond amyloid to tackle atypical Alzheimer’s variants, neuroinflammation, and systemic factors for personalized care.
Why Anti-Amyloid Alzheimer's Treatments Need a Lifestyle Boost
Discover why new Alzheimer's antibody treatments like lecanemab aren't enough on their own and why daily habits like exercise and diet play a critical role in brain health.
Why Trust is the Missing Ingredient in Medical Research
For decades, the world of medical research has faced a quiet but massive problem: most clinical trials don't look like the real world. While science moves faster than ever, the way we find people to participate in life-saving studies is stuck in the past. This is especially true for underrepresented communities—including Black, Hispanic, and Asian Americans
A Turning Point in the Fight Against Alzheimer's
For decades, the search for an Alzheimer's cure focused almost entirely on one thing: clearing out a protein called amyloid that builds up in the brain. But as we move through 2026, the landscape of medical research is undergoing a massive and hopeful transformation.